Polly A. Murphy bought $25k of AVIR
director at Atea Pharmaceuticals, Inc.. 6,100 shares at an average of $4.17, traded May 18, 2026, filed May 21, 2026.
Score components
- +15RoleDirector
- +5Trade size$25k at market
- +3Relative to holdingsHoldings up 7%
- +8Price context33% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-235039, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 18, 2026 | POpen-market purchase Common Stock | +6,100 | $4.17 | $25k | 92,145 | May 21, 2026 |
Related signals
Other insiders at Atea Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 41Moderate | AVIRbuy Atea Pharmaceuticals, Inc. | Polly A. Murphy director | $25k 6,100 shares | +7% | |
| 27Weak | AVIRbuy Atea Pharmaceuticals, Inc. | Franklin M Berger director | $81k 25,000 shares | +6% | |
| 50Moderate | AVIRsell Atea Pharmaceuticals, Inc. | Franklin M Berger director | $1.0M 359,606 shares | -44% | |
| 18Weak | Atea Pharmaceuticals, Inc. | Jean-Pierre Sommadossi President, CEO, and Chairman | $234k 57,969 shares | -1% | |
| 27Weak | AVIRsell Atea Pharmaceuticals, Inc. | Bruce Polsky director | $61k 17,544 shares | -21% | |
| 5Weak | Atea Pharmaceuticals, Inc. | Jean-Pierre Sommadossi President, CEO, and Chairman | $4,024 1,006 shares | -0% | |
| 12Weak | Atea Pharmaceuticals, Inc. | Janet MJ Hammond Chief Development Officer | $54k 14,029 shares | -28% | |
| 11Weak | Atea Pharmaceuticals, Inc. | John Vavricka Chief Commercial Officer | $45k 11,819 shares | -35% | |
| 12Weak | Atea Pharmaceuticals, Inc. | Wayne Foster EVP, Chief Accounting Officer | $48k 12,477 shares | -37% | |
| 12Weak | Atea Pharmaceuticals, Inc. | Maria Arantxa Horga Chief Medical Officer | $61k 15,870 shares | -38% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.